BioXcel Therapeutics, Inc. (BTAI)

Over the past six months, BioXcel Therapeutics' stock price has declined significantly. Key events include the release of the Fourth Quarter and Full-Year 2025 financial results, the FDA's acceptance of the sNDA for IGALMI, the enrollment of the first patients in a study of BXCL501, the closing of a registered direct offering, and a reverse stock split.

Information regarding specific demand seasonality for BioXcel Therapeutics' products and services was not found. The nature of their products typically suggests a more consistent demand driven by disease prevalence rather than seasonal fluctuations.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that uses AI and machine learning to develop medicines in neuroscience and immuno-oncology. The company's major products and pipeline candidates include IGALMI, an FDA-approved product for acute agitation; BXCL501, being evaluated for agitation associated with dementia and other conditions; BXCL701, an oral innate immune activator in immuno-oncology; and BXCL502, BXCL503, and BXCL504, additional drug candidates in development.

BioXcel Therapeutics is headquartered in New Haven, Connecticut, USA. The company primarily serves the U.S. market and is evaluating opportunities for global expansion.

BioXcel Therapeutics' brand reputation has been influenced by analyst sentiment and stock performance. The company has a consensus rating of "Hold" from analysts, but the stock price decline and a past fraud investigation have negatively impacted its reputation.

BioXcel Therapeutics has a mixed ownership structure, including institutional, insider, and retail investors. Major institutional owners include Millennium Management Llc and Vanguard Group Inc. The CEO, Vimal Mehta, is the largest individual shareholder.